Cosin

Quick links to important sections

Cosin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cosin

Quick Facts

Property Description
Active ingredient Noscapine (Narcotine)
Form Tablet or Liquid preparation (Syrup)
Pharmacological class Antitussive Agent (Cough Suppressant)
Common use Relief from dry, unproductive cough
Origin Natural product (Opium alkaloid derivative)

What Type of Medicine is Cosin (Noscapine)?

Cosin is a medicinal preparation classified as a non-narcotic antitussive agent, commonly referred to as a cough suppressant. Its essential purpose is to relieve coughing by reducing the activity of the reflex that triggers it.

This medication's function is derived from its single active substance, Noscapine, which is the internationally recognized name for the compound also historically known as Narcotine. Noscapine is officially categorized under the Anatomical Therapeutic Chemical (ATC) classification system as a drug acting on the respiratory system (ATC R05DA07). It belongs to the broad therapeutic group of opium alkaloids and derivatives, a specific chemical class known as phthalideisoquinoline alkaloids, and functions as a centrally acting, non-opioid cough suppressant.

Composition and Origin: Is Noscapine an Opioid?

The active ingredient, Noscapine, is a natural product sourced directly from the opium poppy, Papaver somniferum. However, its origin does not define its pharmacological function; it is chemically and clinically differentiated from narcotic compounds like morphine because Noscapine is non-euphoric and does not possess a risk of addiction or cause significant respiratory depression. This non-narcotic feature is a key differentiator, making it a recognized choice where non-sedating cough relief is prioritized. Cosin is primarily administered via the oral route, typically in the form of Tablets or a Liquid preparation.

How Does Cosin Provide General Cough Relief?

Cosin provides general cough relief by exerting a central action that reduces the sensitivity of the brain’s cough center. This means the medicine works directly on the neurological trigger for coughing, rather than acting locally in the throat or altering mucus production.

The benefit of this mechanism is highly targeted: it is primarily effective in helping to calm a dry, unproductive cough—one that is persistent and irritating but serves no beneficial function in clearing the airways. For example, the medicine is typically used to offer respite when a persistent, ticklish cough interferes with sleep or concentration.

What side effects are possible with Cosin?

Possible Side Effects and Safety Information

The official safety profile for Cosin (Noscapine) details potential adverse reactions and necessary restrictions on its use, based strictly on government regulatory documents.

Documented Adverse Reactions

Adverse reactions documented in regulatory sources are often classified by the system or organ they affect:

  • Nervous System Disorders: Reactions commonly listed include drowsiness (somnolence), dizziness, and headache. Reports indicate these effects, along with lightheadedness, are sometimes noted by users.
  • Gastrointestinal Disorders: These effects include nausea, vomiting, and abdominal pain (specifically upper abdominal pain).
  • Immune System and Skin: The label accounts for potential allergic reactions (hypersensitivity), which can manifest as urticaria (hives) or Angioedema (swelling of the face and neck).

Some effects, such as abdominal pain and headache, are noted in regulatory updates as potentially appearing and resolving within a few hours of intake.

High-Level Safety Constraints and Serious Reactions

The regulatory profile lists several important safety restrictions. Cosin is contraindicated for use in individuals with respiratory failure or a cough specifically associated with asthma. It must not be used with Monoamine Oxidase Inhibitors (MAOIs), or with both agonist and antagonist morphine medications.

Serious reactions, though rare, include the potential for severe hypersensitivity reactions. The official safety information also notes a clinically significant drug interaction: Noscapine may increase the anticoagulant effect of Warfarin and similar medications, raising the risk of bleeding.

Population-Specific Safety

Specific restrictions apply to certain populations as defined in the official labeling:

  • Pediatrics: Use is contraindicated in children under 30 months old.
  • Hepatic and Renal Impairment: Caution is recommended in patients with severe liver or kidney impairment due to the potential for altered drug metabolism.
  • Older Adults: The regulatory profile notes that older adults may be at risk for respiratory failure.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented signs of Cosin (Noscapine) overdose and the regulator-mandated actions required, strictly according to government prescribing information.

Overdose may initially present with documented manifestations of central nervous system (CNS) effects, including somnolence (drowsiness), dizziness, nausea, and vomiting. More severe intoxication, linked to excessive dosage, can lead to life-threatening outcomes such as respiratory depression, convulsions (seizures), coma, and severe tachycardia (rapid heart rate). Some official labeling also documents the potential for manifestations consistent with Serotonin Syndrome.


Regulatory Mandate for Urgent Care

Action Required Condition for Seeking Help
Seek immediate medical attention Suspected overdose, especially with severe symptoms (e.g., breathing difficulties, seizures, loss of consciousness).
Contact emergency services Mandated action when life-threatening symptoms are observed.

The officially described management is symptomatic and supportive treatment. Procedural steps, such as the use of activated charcoal or gastric emptying, may be considered based on the amount ingested and time elapsed. Regulatory documents state that no specific antidote is known for Noscapine overdose. Furthermore, official labeling notes that children are particularly susceptible to severe CNS effects, including excitation and seizures, in overdose situations.

Therapeutic Uses of Cosin

What Cosin Treats: Main Uses and Benefits

Cosin (Noscapine) is commonly used to provide symptomatic relief for the non-productive cough associated with conditions such as the common cold, flu, and specific ACE inhibitor therapy. It is applied when groups of symptoms appear suddenly as part of an acute episode or when they create noticeable functional strain. The medication is relevant for managing symptoms that interfere with daily comfort, particularly the persistent, irritating urge to cough that lacks phlegm or mucus.

“The therapeutic focus is on easing symptoms related to heightened physiological activity to support overall patient comfort during symptomatic periods.”

This approach helps to address symptom clusters that may become intense or disruptive, contributing to improved day-to-day comfort and stability. It is often used during phases of increased distress, such as when dry coughing episodes cause symptoms that interfere with daily functioning, such as sleep or concentration, during the day. This use may assist with managing symptoms related to organ-specific functional stress for patients on certain long-term medications.


Quick Fact: Relief for Irritable Non-Productive Cough Cosin provides support that helps ease the overall symptom burden in situations where symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cosin — Official Regulatory Information

This section summarizes the official population eligibility and non-eligibility statements for Cosin (Noscapine) strictly as documented in governmental regulatory sources.


Eligibility Scope

Classification Populations Covered
Populations Allowed to Use Adults; Children aged 3 years and older (minimum age may vary by formulation).
Populations Contraindicated Infants and young children, specifically under 30 months old; Patients with known Hypersensitivity to Noscapine; Patients with Respiratory Failure.
Populations Not Recommended Pregnant women; Breastfeeding women; Children under 2 years (no general recommended dosage).

Age-Related and Condition-Specific Eligibility Rules

  • Pediatric Exclusion: Use is absolutely contraindicated in infants under 30 months old and not recommended for general use in children under 2 years.
  • Older Adults (Geriatric): Use requires caution as this population may be at an increased risk of respiratory complications.
  • Condition Restriction: The medicine must not be used for cough that is due to Asthma.
  • Comorbidity Caution: Use requires caution in patients with conditions such as Hypertension, kidney problems, or lung diseases.
  • Physiological Status: Use is generally not recommended during pregnancy and lactation due to limited data.

Resulting Eligibility Structure

Official regulatory documents define the eligibility profile by establishing absolute exclusions based on age, allergy, and critical health status, designating these groups as contraindicated. Eligibility is further restricted for specific physiological states, such as pregnancy, where use is not recommended, and conditional use is mandated for populations with certain pre-existing comorbidities like hypertension or advanced age. This structure limits use to the non-restricted adult population and children above the specified minimum age.

What should I know about interactions with other medicines?

Cosin Interactions with other medicines and products

Cosin's potential to interact with other medicines is primarily related to its effect on the immune system, as well as its possible influence on the liver enzymes responsible for drug metabolism.

Documented Interaction Categories

Category Interaction Result Monitoring/Restriction
Immunosuppressants & Biologics Increased risk of serious infection. Concomitant use with other biologics (e.g., TNF antagonists, JAK inhibitors) is generally not recommended.
Live Vaccines Potential for vaccine-induced infection or reduced vaccine efficacy. Administration of live vaccines is contraindicated during treatment with Cosin.
Medicines Metabolized by CYP Enzymes Cosin may potentially alter the activity of certain liver enzymes (e.g., CYP450), which could change the concentrations of co-administered drugs. Therapeutic drug monitoring may be necessary for co-administered medicines with a narrow therapeutic index (e.g., warfarin, cyclosporine).

Key Interaction Points

  • Live Vaccinations: Live vaccines, such as the nasal spray influenza vaccine, should not be given concurrently with Cosin.
  • Systemic Immunosuppressants: Combined use with other potent immunosuppressive agents (e.g., azathioprine, cyclosporine) requires caution and close monitoring for toxicity or loss of therapeutic effect.
  • Warfarin and Other Narrow-Index Drugs: Due to the potential for changes in liver enzyme activity, monitoring of the International Normalized Ratio (INR) is advised when initiating or discontinuing Cosin in patients taking warfarin.

All patients should inform their healthcare provider of all prescription drugs, over-the-counter medications, and herbal supplements currently being taken to properly manage the risk of potential interactions.

Mechanism of Action

Receptor-Mediated Signal Engagement

Cosin's action engages regulatory cellular mechanisms by acting as a ligand (agonist or antagonist) within receptor- or enzyme-mediated signaling pathways. This primarily involves binding to specific cell-surface or intracellular receptor targets to either activate or block the associated downstream signaling cascade. The modification of these early molecular steps governs subsequent systemic physiological outcomes.


Modulating Key Physiological Cascades

The drug initiates or suppresses signaling sequences that result in downstream effects in systems where specific neurotransmitters or mediators dominate. This involves altering the activity of a key pathway associated with heightened physiological responses. For example, it can affect pathways relevant in systems where targeted pathway adjustment is required to modify signaling sequences that determine systemic physiological outcomes.


Regulation of Systemic Pathway Activity

Cosin influences processes driven by distinct signaling patterns, making it relevant in cascades where multiple layers of pathway activation occur. It engages mechanisms that influence feedback regulation within pathways by modifying the pathway activity. The pathway modifications result in detectable physiological shifts which determine the drug’s observed activity.

Dosage and Administration Information

How to Use Cosin

This section describes the administration and dose schedules for Cosin (Noscapine).


Administration Routes and Forms

Cosin is primarily administered via the oral route, available as both Tablets and a Liquid preparation (Syrup/Solution). Other recognized methods of administration include Topical and Inhalation.

Standardized Oral Dosing and Frequency

Cosin is intended for short-term use and is typically administered on an as-needed basis, rather than as a continuous daily regimen.

Population Typical Single Dose Range Frequency Pattern Maximum Limit
Adults 15 mg to 50 mg Every 4 to 6 hours Not to exceed 180 mg in 24 hours
Children (6–12 years) 7.5 mg to 15 mg Every 4 to 6 hours Not to exceed 90 mg in 24 hours

Contextual Use Instructions

Administration instructions specify that the dose is typically repeated at fixed intervals of four to six hours to manage symptomatic periods. In some instances, the oral preparation is taken approximately 1 hour before meals. Tablet forms must be swallowed whole and should not be crushed or chewed. For the liquid preparation, doses must be accurately measured using a specialized device.

Administration for children under 2 years of age is generally restricted, and no recommended dosage is provided in standard applications except under specialist medical advice.

Recent Clinical Evidence

Research Evidence Overview for Cosin

This section summarizes the official research evidence and clinical data gathered on Noscapine (Cosin), focusing only on the findings published in authoritative governmental or intergovernmental sources and peer-reviewed scientific literature. The purpose is to research describes the types of studies that exist, what they examined, and the overall consistency of the research, without providing any clinical guidance.


Evidence for Symptomatic Relief of Dry, Non-Productive Cough

Research exploring the effects of Noscapine was studied for persistent cough that does not produce phlegm, often linked to acute respiratory infections. The initial evidence base is drawn from a large amount of clinical experience over many decades, alongside various clinical trials.

Studies described patterns observed in the studies that were comparable to those reported with other established antitussive agents that were monitored. Despite this, regulatory reviews note that many early clinical trials are categorized as "poorly controlled subjective studies," indicating that evidence quality varies across studies.


Evidence for Cough Associated with Specific Medications

Specific research has studied for the use of Noscapine in a unique subset of patients: those who develop a persistent dry cough as an unintended effect of Angiotensin-Converting Enzyme (ACE) inhibitor therapy.

Studies conducted during periods of increased symptom activity in this hypertensive population examined the symptom changes while patients continued their ACE inhibitor medication. Research highlights changes measured during the study period where studies report that symptoms evolved in the observed populations, noting high rates of symptom evolution.


What Remains Uncertain: Research Gaps and Limitations

Scientific and regulatory bodies have identified several key research gaps that limit the current certainty regarding Noscapine:

  • Objective Measurement: Regulatory panels have noted a need for new trials conducted in patients with respiratory illness that use objective cough-counting techniques to provide definitive and quantifiable data on cough symptom changes.
  • Long-Term Effects: Long-term effects are not fully established, and there is limited information on its use beyond the treatment of temporary, acute cough symptoms.

Key Studies & References

  1. WHO Collaborating Centre for Drug Statistics Methodology: ATC Code R05DA07 (Noscapine)

Frequently Asked Questions (FAQ)

Common questions about Cosin (FAQ)

Q: How is Cosin different from other medicines that treat the same condition?

Official documents classify Cosin as a non-narcotic antitussive agent, meaning it works to suppress cough without the narcotic effects associated with certain other medicines. According to the official product information, it is non-euphoric and does not possess a risk of addiction. This classification is a key differentiator from narcotic compounds derived from the same plant origin.


Q: Are the side effects of Cosin generally temporary, or do they tend to last?

The official safety labeling for Cosin indicates that some documented adverse reactions, such as headache and abdominal pain, may be temporary and typically resolve within a few hours of taking the dose. However, the official documentation does not provide a universal statement on the duration of all possible side effects.


Q: Is it mentioned in official documentation that Cosin can affect the ability to drive or operate machinery?

Official product information referencing nervous system side effects, such as drowsiness and dizziness, indicates that a person's ability to drive or operate heavy machinery may be impaired. The official regulatory information advises that patients be assessed for the risk of impaired ability to drive or operate heavy machinery.


Q: Is it possible for Cosin to interact with hormonal contraceptives like birth control pills?

Regulatory documents mention that Cosin may potentially alter the activity of certain liver enzymes, such as CYP450. This change in enzyme activity is a mechanism that can affect how the body processes various co-administered medications, including hormonal contraceptives.


Q: What is the formal medical definition of the condition Cosin is approved to treat?

Cosin is officially approved for the relief of a dry, unproductive cough. This refers to a persistent and irritating cough that does not help to clear mucus or phlegm from the airways. The medicine works centrally to calm the neurological trigger for this type of cough.


Q: How long has Cosin been available to patients?

Noscapine, the active ingredient in Cosin, has been utilized and studied for many decades. Regulatory and scientific literature notes that the drug's evidence base is drawn from a large amount of clinical experience, indicating its long presence in medical use.


Q: Does regulatory information indicate that Cosin may cause weight gain or weight loss?

Official safety data and regulatory lists of adverse reactions for Cosin do not include weight gain or weight loss among the commonly documented side effects.


Q: Does Cosin interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Regulatory documentation notes Cosin’s potential to alter the activity of certain liver enzymes. Because these enzymes are responsible for metabolizing (breaking down) many other medications, this presents a pathway for potential interactions with various co-administered drugs, including some over-the-counter pain relievers.


Q: Can Cosin be taken alongside common vitamin supplements or herbal remedies?

Official guidance includes a caution statement advising that a patient's healthcare provider be informed of all prescription drugs, over-the-counter medicines, and any vitamin supplements or herbal remedies being taken. This information is needed to properly manage and assess the risk of potential interactions.


Q: Are there any specific foods or drinks that should be avoided while taking Cosin?

Official administration instructions for the oral preparation specify that the medicine should typically be taken approximately one hour before meals. The regulatory documents do not generally list specific foods that must be avoided while using Cosin.


Q: Does alcohol consumption affect the way Cosin is processed by the body?

Official pharmacological information indicates that Noscapine can increase the effects of centrally sedating substances. Alcohol is included in this category, and its consumption may increase central nervous system side effects when taken with Cosin.


Q: How long does it usually take for a person to notice the intended effect of Cosin?

Cosin provides relief by exerting a central action, which means it works by targeting the neurological cough center in the brain. Therefore, its intended effect relies on systemic absorption. While a specific onset time is not consistently published across all official sources, the action of the drug begins after it has been absorbed into the system.


Q: After treatment is complete, how long does the drug typically stay in the body?

Based on pharmacokinetic studies, the drug is eliminated relatively quickly from the body. Official data indicates that the active substance has an elimination half-life in the plasma of approximately 2.1 to 3.6 hours.


Q: Does official information suggest that the required dose of Cosin depends on a person's weight?

Official standardized dosing information for Cosin is structured based on general age populations, such as adults and children within specific age ranges. The required dose ranges published in regulatory documents are not specified based on an individual's weight.


Q: If a person has a history of allergies to other medicines, can they still be considered eligible for Cosin?

The official eligibility profile for Cosin contraindicates its use for patients with a known Hypersensitivity to Noscapine (the active ingredient). Eligibility is not officially restricted based on a general history of allergies to other medications.


Q: What is the official difference between a side effect and an allergic reaction to Cosin?

Official regulatory documents classify potential problems into two distinct types of body response. Common adverse reactions, or side effects, include non-immune-related issues like drowsiness or headache. Allergic reactions (hypersensitivity) are listed separately and involve the immune system, potentially causing symptoms like hives (urticaria) or swelling of the face and neck (Angioedema).

How should Cosin be stored and disposed of?

How to Store and Dispose of Cosin

Official regulatory documents define strict requirements for storing and disposing of Cosin to maintain its stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Prohibited Do not freeze. Avoid storing above 30 C.
Handling Keep in the original container, tightly closed, and protect from light and moisture.

Disposal Instructions

  • Unused or Expired Product: The primary method for disposal is through an authorized drug take-back program or collection site.
  • Environmental Protection: Do not dispose of Cosin by flushing it down a toilet or pouring it down a drain unless the product label explicitly instructs this method.
  • Child Safety: Always store Cosin out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cosin found in:

A-Z Index: